ImClone Systems Incorporated · New York, NY United States
Company Description
More Companies in: New York, New York
More Companies in These Related Industries: Biologics Mfg, Pharmaceutical Preparation Mfg
View ImClone Systems Incorporated Locations On A US Map
This link will open in a new window
This link will open in a new window ImClone Systems has one drug and it is making the most of it. The drug development company's only product on the market, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb in North America and with Merck KGaA elsewhere. ImClone is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. The company is also working on additional oncology-related antibody therapies. In 2008 ImClone was acquired by Eli Lilly for $6.5 billion, after rejecting bids from Bristol-Myers Squibb. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
ImClone Systems Incorporated Reports
No subscription, no problem.
Download presentation-ready reports for this company now.
Download presentation-ready reports for this company now.
From company profiles to the competitive landscape, Hoover’s offers immediate access to individual reports.
Key ImClone Systems Incorporated Financials
| Company Type | Subsidiary Headquarters |
| Fiscal Year-End | December |
| Employees | 1,128 |
ImClone Systems Incorporated Executives
29 executives listed for ImClone Systems Incorporated's New York, NY location.
| Title | Name & Bio | Contact |
| CEO | John Johnson | |
| VP, General Counsel, and Chief Compliance Officer | Gregory Mayes | |
| EVP and Chief Medical Officer | Eric Rowinsky |
Competition
Competitive Landscape for ImClone Systems Incorporated
Demand often depends on the income of consumers or the profitability of business customers, because many technology products and services are expensive. The profitability of individual companies is driven by their ability to develop and market new products. Large companies often have advantages in access to capital and marketing. Small companies can compete successfully if they have expertise in a particular field of knowledge. The industry is capital-intensive: average annual revenue per worker is nearly $300,000. To read the full description, subscribe now.Top ImClone Systems Incorporated Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!